Clinical Trials Browser

Interventional × adavosertib × Gastrointestinal × Clear all

NCT02465060 2026-06-03

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)

Phase 2 Active not recruiting

6,452 enrolled 1 FDA

BreastCNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckLymphoidOther hematologic neoplasmPlasma cellThoracic

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Colonic Neoplasms, Esophageal Neoplasms, Glioma, Carcinoma, Hepatocellular, Lung Neoplasms, Lymphoma, Melanoma, Multiple Myeloma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Rectal Neoplasms, Stomach Neoplasms, Thyroid Neoplasms, Uterine Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Hematologic Neoplasms

NCT04460937 2026-04-29

Testing the Addition of an Anti-cancer Drug, Adavosertib, to Radiation Therapy for Patients With Incurable Esophageal and Gastroesophageal Junction Cancers

Phase 1 Active not recruiting

4 enrolled 9 charts

CNSGastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Squamous Cell Carcinoma, Brain Neoplasms, Meningeal Carcinomatosis

NCT01047007 2023-09-21

A Dose Escalation Study of Adavosertib(MK1775) in Combination With 5-FU or 5-FU/CDDP in Patients With Advanced Solid Tumor (1775-005

Phase 1 Terminated

11 enrolled 10 charts

GastrointestinalHead & Neck

Esophageal Neoplasms, Head and Neck Neoplasms, Stomach Neoplasms

NCT02194829 2023-04-25

Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Gemcitabine Hydrochloride With or Without WEE1 Inhibitor AZD1775 in Treating Patients With Previously Untreated Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery

Phase 1/2 Completed

8 enrolled 9 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT05212025 2022-06-14

Adavosertib and Gemcitabine in Advanced Pancreatic

Phase 2 Withdrawn

Gastrointestinal

Pancreatic Neoplasms

NCT02906059 2020-10-12

Study of Irinotecan and AZD1775, a Selective Wee 1 Inhibitor, in RAS or BRAF Mutated, Second-line Metastatic Colorectal Cancer

Phase 1 Completed

Gastrointestinal

Colorectal Neoplasms